The percentage of emergency department (ED) visits for members 13 years of age and older with a principal diagnosis of substance use disorder (SUD), or any diagnosis of drug overdose, for which follow-up care was received.
Two rates are reported:
Any of the following services done with a mental health provider or having a diagnosis of substance use or drug overdose (unintentional) may count as a follow-up visit:
Description | Prescription |
Aldehyde dehydrogenase inhibitor | Disulfiram (oral) |
Antagonist | Naltrexone (oral and injectable) |
Other | Acamprosate (oral; delayed-release tablet) |
Description | Prescription |
Antagonist | Naltrexone (oral) |
Antagonist | Naltrexone (injectable) |
Partial agonist | Buprenorphine (sublingual tablet) |
Partial agonist | Buprenorphine (injection) |
Partial agonist | Buprenorphine (implant) |
Partial agonist | Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film) |
Providers and organizations must submit accurate and complete data in accordance with all billing, coding, and medical policy requirements. HEDIS guidance does not override official coding standards or guarantee reimbursement, as coverage is subject to applicable medical/coding policy and member-specific benefits.
Should you have specific coding or other questions related to the measure, please send your questions to BlueAlliance@bcbsnd.com.
HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).
Updated 8/28/2026